Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Chen Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4330-9716; OpenAlex author ID A5100689172. Sources: OpenAlex.

Their work

Papers
34 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: 3 papers · 2017: 5 papers · 2018: 3 papers · 2019: 4 papers · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers

Papers 34

  1. Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center. Co-author DOI 10.1016/j.surg.2025.109412↗
  2. The development and validation of biomarkers-based scoring systems for predicting early recurrence in patients with borderline resectable pancreatic cancer und… Co-author DOI 10.21037/gs-2024-500↗
  3. Ubiquitin-specific protease 7 maintains c-Myc stability to support pancreatic cancer glycolysis and tumor growth. Co-author DOI 10.1186/s12967-024-05962-6↗
  4. Recurrence scoring system predicting early recurrence for patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy and portomesenteric vein res… Co-author DOI 10.4240/wjgs.v16.i10.3185↗
  5. Postoperative serum tumor markers-based nomogram predicting early recurrence for patients undergoing radical resections of pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v16.i10.3211↗
  6. hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients. Co-author DOI 10.1186/s12876-023-02666-x↗
  7. The expression and survival significance of sodium glucose transporters in pancreatic cancer. Co-author DOI 10.1186/s12885-021-09060-4↗
  8. Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in … Co-author DOI 10.3389/fsurg.2022.890412↗
  9. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study. Co-author DOI 10.1080/07357907.2021.1950755↗
  10. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41416-020-0929-0↗
  11. Single-nucleotide polymorphisms based genetic risk score in the prediction of pancreatic cancer risk. Co-author DOI 10.3748/wjg.v26.i22.3076↗
  12. Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncologic… Co-author DOI 10.4240/wjgs.v12.i12.491↗
  13. High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ejso.2018.09.020↗
  14. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. Co-author DOI 10.1186/s13046-019-1088-0↗
  15. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. First author DOI 10.3748/wjg.v25.i23.2839↗
  16. Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: A propensity score matching analys… Co-author DOI 10.3892/ol.2019.10822↗
  17. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/1533034617748429↗
  18. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. Last author DOI 10.2147/ijn.s166769↗
  19. Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8041↗
  20. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. Last author DOI 10.1016/j.ijsu.2017.10.066↗
  21. An evaluation study of reported pancreatic adenocarcinoma risk-associated SNPs from genome-wide association studies in Chinese population. Co-author DOI 10.1016/j.pan.2017.09.009↗
  22. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival. Last author DOI 10.1016/s1499-3872(16)60168-6↗
  23. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein invo… Co-author DOI 10.18632/oncotarget.20847↗
  24. Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases. Last author DOI 10.2147/ijn.s131295↗
  25. Application of Deuteporfin in the Metastatic Lymph Node Mapping of Pancreatic Cancer: An in vivo Study. Co-author DOI 10.1111/php.12574↗
  26. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. First author DOI 10.3748/wjg.v22.i45.10024↗
  27. Circulating tumor cells in pancreatic cancer patients: efficacy in diagnosis and value in prognosis. Co-author PMID 27755967↗
  28. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Co-author DOI 10.2147/ijn.s93835↗
  29. Characterization of the role of the photosensitizer, deuteporfin, in the detection of lymphatic metastases in a pancreatic cancer xenograft model. Co-author DOI 10.3892/ol.2015.3441↗
  30. Magnetic graphene-based nanotheranostic agent for dual-modality mapping guided photothermal therapy in regional lymph nodal metastasis of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.07.064↗
  31. Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel. Co-author DOI 10.3748/wjg.v20.i28.9476↗
  32. MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. Co-author DOI 10.4161/cbt.29706↗
  33. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Co-author DOI 10.1007/s12032-013-0700-y↗
  34. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2013.2516↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deliang Fu · 23 shared papers, 2013–2024 · strength 2.49
  2. Hang He · 11 shared papers, 2013–2025 · strength 1.41
  3. Feng Yang · 12 shared papers, 2013–2025 · strength 1.37
  4. Jichun Gu · 10 shared papers, 2017–2024 · strength 1.21
  5. Lie Yao · 11 shared papers, 2013–2020 · strength 0.90
  6. Yongjian Jiang · 8 shared papers, 2013–2025 · strength 0.83
  7. Ji Li · 7 shared papers, 2013–2024 · strength 0.81
  8. Hengchao Li · 6 shared papers, 2015–2024 · strength 0.73
  9. Xinzhe Yu · 8 shared papers, 2015–2023 · strength 0.73
  10. Di Yang · 11 shared papers, 2013–2020 · strength 0.68
  11. Deliang Fu · 6 shared papers, 2015–2025 · strength 0.68
  12. Yishen Mao · 5 shared papers, 2018–2024 · strength 0.67
  13. De-Liang Fu · 2 shared papers, 2024–2025 · strength 0.53
  14. Zhibo Xie · 5 shared papers, 2016–2019 · strength 0.51
  15. Junyuan Deng · 3 shared papers, 2021–2022 · strength 0.45
  16. Lei Kong · 3 shared papers, 2021–2022 · strength 0.45
  17. Jiali Du · 3 shared papers, 2021–2022 · strength 0.45
  18. Ji Li · 5 shared papers, 2014–2022 · strength 0.43
  19. Yifan Zhang · 3 shared papers, 2017–2019 · strength 0.32
  20. Ji Li · 1 shared paper, 2025 · strength 0.30
  21. Zhongyi Guo · 3 shared papers, 2017–2018 · strength 0.24
  22. Rongkun Li · 1 shared paper, 2024 · strength 0.23
  23. Xi Xiao · 1 shared paper, 2024 · strength 0.23
  24. Xinyu Huang · 1 shared paper, 2023 · strength 0.22
  25. Wei Wang · 1 shared paper, 2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.